Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

DOI: https://doi.org/10.1186/s40035-025-00465-wKey Discussion Points:1. Overview of Current Landscape- Three FDA-approved second-generation antibodies: Aducanumab, Lecanemab, Donanemab- Lecanemab recently received traditional FDA approval- Represents validation of amyloid cascade hypothesis2. Individual Antibody Profiles:Aducanumab- Derived from memory B cells of both healthy and cognitively impaired individuals- Targets amyloid beta plaques (amino acids 3-7)- Shows dose-dependent reduction in amyloid beta- Notable occurrence of ARIA side effectsLecanemab- Derived from mouse antibody MA158- Targets amyloid beta protofibrils (amino acids 1-16 and 21-29)- ClarityAD trial showed slowing of cognitive decline- Affects both amyloid beta and phosphorylated tau levelsDonanemab- Targets N-terminal pyroglutamate of amyloid beta- Trailblazer ALZ trials showed significant amyloid reduction- Initially denied accelerated approval due to limited patient data- Later trials showed more positive findingsGantenerumab- Engineered using Hucal phage display technology- Targets amyloid beta fibrils (amino acids 3-11 and 18-27)- Mixed results: Early trials showed amyloid reduction but larger Graduate I/II trials didn't show significant cognitive improvement- Dosing and delivery methods may have affected results3. Key Challenges:ARIA (Amyloid-Related Imaging Abnormalities)- Manifests as edema (ARIA-E) or hemorrhage (ARIA-H)- Involves complement cascade and FCR-mediated signaling- Major safety concern requiring careful monitoringBlood-Brain Barrier- Limits antibody penetration- Requires high doses which can increase ARIA risk4. Future Directions:Innovative Strategies:- Antibody Drug Conjugates (ADCs) combining antibodies with targeted payloads- Targeted Protein Degradation (TPD) approaches- Modified antibodies like α Aβ-Gas6 fusion protein- Personalized therapy approaches based on biomarkers- Combination therapies targeting multiple disease aspectsBiomarker Development:- MicroRNA-based early detection- Blood-based testing potential- Importance of early interventionConclusion:The field shows promise but requires continued research to optimize safety and efficacy. Future success likely lies in combination approaches and personalized treatment strategies.